Related Experiment Video
Updated: May 10, 2026
12:19
Co-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle
Published on: June 7, 2024
MMV in partnership: the Eurartesim® experience.
David Ubben1, Elizabeth M Poll
1Medicines for Malaria Venture, 20 Rte de Pré-Bois, PO Box 1826, Geneva 1215, Switzerland.
Malaria Journal
|June 21, 2013
Summary
A public-private partnership successfully developed dihydroartemisinin-piperaquine (Eurartesim®) for malaria treatment. This collaboration enabled wider access to the essential medicine in endemic regions.
Area of Science:
- Global health
- Pharmaceutical development
- Infectious disease research
Background:
- Public-private partnerships are crucial for developing essential medicines.
- Medicines for Malaria Venture (MMV) and Sigma-Tau partnered to advance dihydroartemisinin-piperaquine (Eurartesim®).
- Overcoming regulatory hurdles was key to expanding malaria treatment access.
Purpose of the Study:
- To describe the development of dihydroartemisinin-piperaquine (Eurartesim®) through a public-private partnership.
- To highlight the achievement of international regulatory approval for Eurartesim®.
- To demonstrate enhanced access to malaria treatment in endemic countries.
Main Methods:
- Collaboration between MMV, Sigma-Tau, and other academic/industrial partners.
- Development of dihydroartemisinin-piperaquine to international regulatory standards.
- Submission of dossiers for marketing authorization and WHO prequalification.
Main Results:
- Achieved European Medicines Agency (EMA) marketing authorization for Eurartesim® in 2011.
- Facilitated the first delivery to Cambodia in July 2012, aiding artemisinin resistance management.
- Ongoing development of a pediatric dispersible formulation.
Conclusions:
- The product development partnership model effectively leverages diverse expertise for common goals.
- Successful uptake of Eurartesim® by public health systems presents ongoing challenges.
- Further partnerships may be needed to ensure sustained access and effective malaria treatment.
Related Concept Videos
01:42The Extracellular Matrix
Overview
01:29The Extracellular Matrix
Overview
In order to maintain tissue organization, many animal cells are surrounded by structural molecules that make up the extracellular matrix (ECM). Together, the molecules in the ECM maintain the structural integrity of tissue as well as the remarkable specific properties of certain tissues.
Composition of the Extracellular Matrix
The extracellular matrix (ECM) is commonly composed of ground substance, a gel-like fluid, fibrous components, and many structurally and functionally diverse...
In order to maintain tissue organization, many animal cells are surrounded by structural molecules that make up the extracellular matrix (ECM). Together, the molecules in the ECM maintain the structural integrity of tissue as well as the remarkable specific properties of certain tissues.
Composition of the Extracellular Matrix
The extracellular matrix (ECM) is commonly composed of ground substance, a gel-like fluid, fibrous components, and many structurally and functionally diverse...
00:53Migration
Migration is long-range, seasonal movement from one region or habitat to another. This common strategy, carried out by many different organisms around the world, is an adaptive response that typically corresponds to changes in an organism’s environment, like resource availability or climate. Migrations can involve huge groups of thousands of animals as well as single individuals traveling alone and can range from thousands of kilometers to just a few hundred meters.